JWCAR129 / JW (Cayman) Therap - LARVOL DELTA

JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129 (PRNewswire) - “JW Therapeutics…announced that it has received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for a clinical trial of BCMA-targeted Chimeric Antigen Receptor (CAR) T cell JWCAR129 in treating relapsed or refractory multiple myeloma (R/R MM).”

New trial • Hematological Malignancies • Multiple Myeloma • Oncology

JW Therapeutics’ second anti-BCMA CAR-T under trial review in China (GBI Health) - "The Center for Drug Evaluation (CDE) website indicates that the clinical trial filing by JW Therapeutics for JWCAR129, a BCMA-targeted chimeric antigen receptor (CAR)-T cell therapy, has been accepted for review. JW is a cell therapy-focused joint venture (JV) between the now Bristol-Myers Squibb owned Juno Therapeutics and China-based Contract Research Organization (CRO) WuXi AppTec."

New trial • Oncology